United States Department of Agriculture: Animal and Plant Health Inspection Service
United States Department of Agriculture Wildlife Services: Staff Publications
Accessibility Remediation
If you are unable to use this item in its current form due to accessibility barriers, you may request remediation through our remediation request form.
Document Type
Article
Date of this Version
5-1-2008
Abstract
Before immunocontraceptives can be considered safe to use on wildlife species, potential health risks should be assessed. Gonadotropin-releasing hormone (GnRH) immunocontraceptive has successfully reduced fertility of white-tailed deer (Odocoileus virginianus); however, associated deer physiology has rarely been examined. We conducted gross necropsy examinations, histology, and blood chemistry comparisons on euthanized deer previously vaccinated with immunogenic GnRH (n = 18 females and n = 4 males), or left as untreated controls (n = 7 females and n = 6 males). Granulomas were found at injection sites of most deer, even 3 years post-treatment. There were no significant differences in ovary (F2,22= 0.31, P = 0.73), or pituitary weights (F2,22 = 0.30, P = 0.75) between treatment groups. Ovaries from control females had significantly more secondary follicles (F2,21 = 20.56, P ≤ 0.001), but not Graafi an follicles (F2,22= 2.22, P = 0.13). Immunized males had significantly lower mean testes weights, a number of morphologic abnormalities, and varying degrees of aspermatogenesis with fewer mature spermatozoa. We do not recommend treating male deer with anti-GnRH immunocontraceptive vaccines.
Comments
Published in Human–Wildlife Conflicts 2(1):68–79, Spring 2008.